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Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. Because
of inadequate efﬁcacy of pharmacological therapy, catheter ablation of AF has evolved dramatically
over the last decade. Although the success rate of ablation has improved, the ablation strategy is still
extensive, and the ablation procedure is technically challenging. In the past decade, electrophysiologists
were eager to obtain high success rates with extensive ablation. In the present decade, further
clariﬁcation of the complex mechanism of AF is required to make ablation of AF safer and much more
efﬁcient. Because the mechanism of AF is very complex, and even somewhat mysterious, it may not be
easy to attain a better understanding of the mechanism involved or to discover better guidance for
catheter ablation. However, it is important to note that research into AF leads to better understanding
of other cardiac and non-cardiac diseases because AF develops multifactorially in association with
underlying systemic pathophysiologies.
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Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia
encountered in clinical practice. The number of people with AF
in the United States is currently estimated at 2.4 million, and the
projected number with AF may exceed 10 million by 2050 [1,2].rt Rhythm Society. Published by E
: þ81 29 853 3143.
).Treatment for AF is also an important societal issue in that it
represents a signiﬁcant health care cost, currently estimated to be
about h13.5 billion annually in the European Union [4]. Increased
stroke risk in the presence of AF, reported to be an almost ﬁvefold
excess [5], makes AF more than a simple cardiovascular disease.
Because of inadequate efﬁcacy of pharmacological therapy,
catheter ablation of AF has evolved dramatically over the last
decade. Although the success rate of ablation has improved to
Z80% with multiple procedures, ablation strategy is still exten-
sive and the ablation procedure is technically challenging,lsevier B.V. All rights reserved.
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past decade was an era when electrophysiologists were eager to
obtain high success rates with extensive ablation. In the present
decade, we are required to further clarify the complex mechan-
isms of AF to make ablation of AF safer and much more efﬁcient.
The ultimate idea is to precisely tailor ablation strategy to the
particular AF mechanism of the patient.Fig. 1. Circumferential pulmonary vein isolation. The 3-dimensional geometry of
the left atrium and pulmonary veins was constructed with the CARTO system.2. Patient selection according to the current guidelines
It is important to recognize that the primary justiﬁcation for an
AF ablation procedure at this time is the presence of symptomatic
AF, with the goal of improving patient quality of life [6]. Although
other reasons for performing AF ablation may be justiﬁed, such as
to decrease stroke risk [7], decrease heart failure risk, and improve
survival, they have not yet been systematically evaluated as part of
a large randomized clinical trial and are therefore unproven. In the
AFFIRM trial, there were no signiﬁcant differences in the all-cause
deaths between rhythm control and rate control using antiar-
rhythmic drug therapy [8]. However, the beneﬁcial effect on the
survival of restoration of sinus rhythm might be offset by the
adverse effects of antiarrhythmic drugs. Therefore, sinus rhythm
may be preferred over rate control if it can be achieved by catheter
ablation. Large prospective multicenter randomized clinical trials
will be needed to deﬁnitively determine whether sinus rhythm
achieved with ablation techniques lowers morbidity and mortality
as compared with rate control alone or treatment with antiar-
rhythmic therapy.3. Patient selection and reverse remodeling after ablation
Left atrial (LA) size has been established as a prognostic marker of
cardiovascular morbidity, mortality, and stroke [9,10]. Studies have
shown that LA enlargement and function can improve, i.e., ‘‘reverse
remodeling,’’ after restoration of sinus rhythm from AF with certain
medications or catheter interventions, including radiofrequency abla-
tion [11–13]. A reduction in LA volume may lead to the improvement
in LA function and exercise tolerance [14,15], decreased likelihood of
thrombus formation [16], and decreased susceptibility to further
atrial arrhythmias [13,17]. Although these beneﬁts need to be proven
by large randomized prospective trials, reverse remodeling after
ablation appears to justify a more aggressive clinical approach even
in less symptomatic patients. Currently, 2 studies have reported
echocardiographic predictors, including LA strain and strain rate, of
LA reverse remodeling after ablation [11,13]. It may be meaningful to
select patients who are likely to achieve reverse remodeling as
suitable candidates for catheter ablation of AF.4. History of ablation strategies
After Haı¨ssaguerre et al. reported that the ectopies from
pulmonary veins (PVs) are responsible for the initiation of AF,
eliminating triggers from the PVs was emphasized as a reasonable
approach to treat AF. However, this approach, directly targeting
focal triggers, was fraught with high recurrence rates due to the
infrequency with which AF initiation could be reproducibly
triggered during the catheter ablation procedure, as well as an
attendant small risk of PV stenosis.
Segmental ostial ablation was the ﬁrst catheter-based techni-
que found to electrically isolate the PVs [18,19]. Ablation was
performed at the ostia of the PVs, and the acute endpoint of PV
isolation (PVI) could be reached in nearly every patient. However,
the long-term success rates are relatively modest (60–70%).
Circumferential PVI (almost equal to wide-area antral PVI), whichinvolves creating circumferential lesions at the PV antra around
the ipsilateral PVs, improved outcomes in patients with both
paroxysmal and persistent AF (Fig. 1) [20]. The superiority of
circumferential PVI over segmental PVI can be explained by the
following: circumferential PVI may extinguish the triggers and
drivers located in less common trigger sites other than the PVs,
including the antral region of the PVs, the vein and ligament of
Marshall, and the posterior LA wall. Circumferential PVI may
impact not only triggers but also the arrhythmogenic substrate
stabilizing the maintenance of AF [21]. The reduction of atrial
muscle mass may make coexistence of multiple reentries impos-
sible (debulking effect) [22]. Moreover, circumferential PVI may
interrupt sympathetic and parasympathetic innervation from the
autonomic ganglia, which have been identiﬁed as potential
triggers for AF [23]. In a series of 349 consecutive patients under-
going circumferential PVI at the University of Michigan, AF was
eliminated in 87% of patients with paroxysmal AF and 75% of
patients with persistent AF [24].5. Do we need complete isolation of all PVs in every patient?
Circumferential PVI results in satisfactory outcomes for ablation
of paroxysmal AF, and electrical isolation of all PVs is currently a
standard approach to the treatment of AF, as recommended by the
expert consensus statement [6]. Complete isolation also seems to
be important for preventing recurrent atrial tachycardia during
follow-up [25–27]. However, it is not clear whether all patients
with AF need to undergo isolation of all PVs. A number of studies
have reported favorable outcomes with an ablation strategy that
does not include PVI. Lemola et al. reported that a successful
outcome after LA ablation was found to be independent of the
number of PVs that were electrically isolated. Therefore, complete
isolation of the PVs was not necessary for a successful outcome
[21]. Oral et al. reported that a tailored ablation strategy that
targeted driver tachycardias and complex electrograms in the
selected PVs resulted in freedom from recurrent AF in 80% of
patients with paroxysmal AF [28]. Pokushalov et al. reported that
selective ganglionated plexi ablation directed by an anatomic
approach resulted in successful outcomes in 80% of patients with
paroxysmal AF [29]. In the Pratola et al. study [29], patients with
persistent AF who underwent PVI and did not have AF recurrence
underwent repeated electrophysiological studies. Notably, PVI
persisted in only 40% of the previously isolated PVs. This study
supported the idea that atrial substrate also plays an important role
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not necessarily mean recurrence of AF [30].
In contrast, there is consensus that in the majority of patients,
AF recurs in association with recovered PV conduction. In a long
follow-up study (median follow-up period of 4.8 years), recovered
PV conduction was observed in 62 of 66 patients (94%) at the 2nd
ablation procedure [31]. The discrepancy in the impact of PVI on
the maintenance of sinus rhythm may be explained by the
interaction of a trigger and a substrate. The presence of AF
substrate in addition to PV reconnection makes the atria more
susceptible to recurrent AF than does PV reconnection alone.
However, little data directly supports this notion because the
actual prevalence of PV reconnections in patients free from
recurrence of AF cannot be evaluated in routine clinical practice.
These studies have indicated that aiming for isolation of all PVs
might be an excessive treatment for some patients. However, the
critical issue is that during the procedure we never completely
know which PV is the trigger that initiates AF (the so-called
arrhythmogenic PV) and which PV is not arrhythmogenic. If we
could determine this, the efﬁciency of AF ablation would improve
dramatically. Advances in technology to make achievement of
isolation of all PVs (so-called prophylactic PVI) safer and easier,
especially in paroxysmal AF, may resolve the issue that the
arrhythmogenic PV critical to the initiation and perpetuation of
AF cannot be deﬁnitively determined during the procedure.6. Relation between hemodynamic status and AF
AF and heart failure create a vicious circle: heart failure
promotes AF, and AF aggravates heart failure. In patients with
symptomatic heart failure, the prevalence of AF ranges from 10 to
30% [32]. The importance of atrial stretch associated with an
increase in atrial pressure in the maintenance of AF has been
reported in animal models [33] and in patients with AF [34]. In
the human study, patients with persistent AF had signiﬁcantly
higher LA pressures than did patients with paroxysmal AF. The
atrial activation rate is known to be higher in patients with
persistent AF than in patients with paroxysmal AF. Higher LA
pressure may result in a greater degree of stretch-related elec-
trical remodeling and an increase in atrial activation rate, making
spontaneous termination of AF less likely.
A potential new risk factor for AF, stiff LA syndrome, was
recently proposed. The syndrome itself was originally reported
in the late 1980s [35]. Its principal feature is that right heart
failure is disproportionate to left heart failure because of
reduced LA compliance or LA diastolic dysfunction. Recent
studies have indicated that one of the causes of the syndrome
was LA ablation for AF [36,37]. Machino-Ohtsuka et al. reported
that pre-existing LA stiffness was related to AF recurrence after
ablation [38]. Using magnetocardiography analysis, Sato et al.
showed that right atrial overload possibly due to decreased LA
compliance after LA ablation was associated with AF recurrence
after ablation [39].
Although a well experienced group reported a very high
success rate of 80% after catheter ablation even in patients with
congestive heart failure [40], the evidence described above suggests
that catheter ablation alone is not sufﬁcient to treat AF in patients
with hemodynamic deterioration. This indicates that pharmacolo-
gical therapies for heart failure, underlying cardiac pathophysiol-
ogy, and hypertension, such as angiotensin-converting enzyme
inhibitors, beta-blockers, statins, and diuretics, are as important as
catheter ablation to decrease susceptibility to AF and to prevent
recurrence of AF after ablation. Obesity and sleep apnea also affect
hemodynamic status and are associated with the prognosis of AF.
Continuous positive air pressure therapy (CPAP) may be effectivefor maintenance of sinus rhythm after ablation [41–43], but this
needs to be tested by randomized prospective trials.7. Advances in technology to isolate PVs
Standard 4-mm-tip ablation catheters were initially used for
LA ablation. Because of the unstable and limited energy delivery
of 4-mm-tip catheters due to the temperature-limited setting,
8-mm-tip catheters were introduced. However, one of problems
in the use of 8-mm-tip catheters was the ambiguity of local
electrograms due to the inclusion of far-ﬁeld electrograms. Since
2000, irrigated-tip catheters have been used in European coun-
tries, and they offer several advantages, including delivery of the
desired power independent of local blood ﬂow [44]. The useful-
ness of this technology has been supported in animal models [45]
and in patients undergoing ablation of AF [46,47].
Efforts continue to improve the efﬁcacy and safety of LA
ablation. Traditional catheter ablation is performed as a single-
tip, point-by-point ablation process. This technique requires a
high degree of operator skill, and procedures are lengthy, often
lasting more than 4 h. Creating reliable continuous transmural
lesions with a single-point catheter is difﬁcult. During the past
decade, a number of alternative ablation systems have appeared,
including cryoablation (with a conventional-tip catheter or a
circular catheter or balloon device), ultrasound ablation, laser
ablation, and an over-the-wire multi-electrode catheter deliver-
ing duty-cycled bipolar and unipolar RF energy. A radiofrequency
ablation catheter capable of real-time tissue–tip contact force
measurements has recently been developed and has garnered
particular attention. The contact force between the catheter tip
and the tissue may affect the clinical outcome of RF ablation for
the treatment of cardiac arrhythmias [48,49]. Insufﬁcient contact
force may result in an ineffective lesion, whereas excessive
contact force may result in complications. Preliminary studies
have indicated that a contact-force sensing catheter is useful for
safe catheter manipulation and reduction of ﬂuoroscopy time. In
the future, it may also increase the effectiveness of ablations by
allowing better control of the lesion size.
Although some of the modalities described are not currently
available in Japan, we should keep in mind that advances in
technology are as important as is understanding of the AF
mechanism in clinical practice.8. Ablation of persistent AF
Because triggers/drivers that originate from the PVs and other
thoracic veins appear to be the primary mechanism of parox-
ysmal AF, ablation strategies that target only thoracic vein
arrhythmogenicity have been effective in the majority of patients
with paroxysmal AF. Additional linear ablation in combination
with circumferential PVI resulted in an increased incidence of LA
atrial tachycardia compared with circumferential PVI alone in
patients with paroxysmal AF [50]. However, elimination of PV
arrhythmogenicity alone has been insufﬁcient to eliminate per-
sistent AF. Although catheter ablation has also evolved into an
effective treatment strategy in patients with persistent AF
[46,47,51,52], the mechanism of persistent AF is still unclear
and ablation efﬁciency remains low.
8.1. Efﬁcacy of ablation of complex fractionated atrial electrograms
(CFAEs)
Nademanee et al. performed ablation of AF that targets CFAEs,
which are deﬁned as electrograms with a cycle length of more
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that were fractionated or displayed continuous electrical activity
[53]. Ablation of CFAEs resulted in termination of AF in 95% of
patients and an excellent clinical outcome, in which 90% of
patients were reported to be free from recurrent arrhythmias.
This ablation strategy is currently applied in combination with
PVI because the clinical efﬁcacy of ablation of CFAEs alone has
been only modest, except in one study [53]. CFAE ablation in
conjunction with PV antral isolation has a higher likelihood of
maintaining sinus rhythm compared with PV antral isolation
alone in patients with persistent AF [51]. Another randomized
study showed that ablation of CFAEs after PV antral isolation did
not have any incremental value over PV antral isolation alone
[54]. The major problem concerning CFAE ablation is that the
deﬁnition of CFAEs is arbitrary and subjective. The coexistence of
the two fundamentally different types of electrograms that
suggest different etiologies in one deﬁnition may not be appro-
priate for targeting a particular mechanism of AF. Although the
authors of some studies tried to objectively detect CFAEs with
custom software and demonstrate differences in the distribution
of CFAEs in the LA between paroxysmal and persistent AF [55,56],
the impact of the objective deﬁnition on clinical outcomes is
unclear. The very high prevalence of CFAEs in the left atrium
suggests that CEAEs alone are a nonspeciﬁc marker of appropriate
target sites for ablation of AF [57]. Therefore, the value of CFAEs
ablation remains controversial.
8.2. Atrial tachycardia and efﬁcacy of linear ablation
Atrial tachycardia is common after catheter ablation of AF.
Among a large number of patients undergoing circumferential
PVI, the prevalence of atrial tachycardia at follow-up was
reported to be 24% [24]. Forty-seven of 50 (94%) consecutive
patients with mitral isthmus-dependent ﬂutter following or
during AF ablation had persistent AF as their primary arrhythmia
[58]. Persistent AF is much more likely to convert to atrial
tachycardia rather than to sinus rhythm during ablation. In 100
patients with persistent AF, atrial tachycardia comprised one-
third of the recurrent arrhythmias after PV antral isolation in
combination with CFAE ablation, and, notably, if patients had a
critical decrease in the dominant frequency (DF) of AF of greater
than 11% or had termination of AF during the procedure, the ratio of
atrial tachycardia to total recurrent arrhythmia increased to 70% [3].
The majority of atrial tachycardias that occurred after circum-
ferential PVI for AF were caused by a re-entrant mechanism.
Mitral isthmus, roof, and septum accounted for 75% of the
ablation target sites for macro-reentrant atrial tachycardias from
the left atrium. The critical isthmus in 115 of 120 (96%) LA re-
entrant atrial tachycardias traversed a prior ablation line, indicat-
ing that they were gap related [25]. There is, however, a hypoth-
esis that the atrial tachycardia that occurs during catheter
ablation of AF is a driver of AF that manifests after elimination
of ﬁbrillatory conduction [59]. Because both reports suggested a
strong correlation between persistent AF and atrial tachycardia,
prophylactic linear ablation accompanied by PVI may improve
ablation outcome irrespective of whether AT is a cause or an
effect. Retrospective evaluation found that linear ablations for
macro-reentrant atrial tachycardia were required in the majority
of patients with persistent AF even if persistent AF was termi-
nated without linear ablation in the index procedure [60]. How-
ever, complete bidirectional block of the mitral isthmus usually
requires aggressive ablation with a combined endocardial and
epicardial approach. Interposition of the circumﬂex artery
between the mitral isthmus and the coronary sinus is associated
with a lower probability of achieving complete mitral isthmus
block [61,62]. Particularly in such cases, this may result in ahigher risk of complications such as cardiac tamponade and
damage to the circumﬂex artery [63]. Assessment of the incre-
mental value of linear ablations after PVI requires a randomized
prospective study.
8.3. Ablation endpoint
Termination of AF during ablation is predictive of freedom
from recurrent AF [46,47,64,65]. However, termination of persis-
tent AF usually requires extensive ablation beyond the PVs,
including ablation of CFAEs and multiple linear lesions. Extensive
ablation is associated with long procedure time, radiation expo-
sure, proarrhythmia, risk of collateral damage, compromise of LA
transport function, and stiff LA syndrome. A multicenter prospec-
tive study showed the conﬂicting result that AF cycle length at
baseline and termination of AF during ablation were not pre-
dictive of long-term sinus rhythm maintenance [66]. Another
study showed that patient age and duration of radiofrequency
energy were independent predictors of the outcomes after multi-
ple procedures, whether or not the AF terminated during the
procedure [67]. In a retrospective analysis of consecutive patients
with persistent AF at the University of Michigan, a decrease in the
dominant frequency of AF by 11% in response to PV antral isolation
and ablation of CFAEs was associated with a probability of main-
taining sinus rhythm that was similar to that when radiofrequency
ablation terminated AF (Fig. 2) [3]. Appropriate patient selection
and an endpoint tailored to each patient are essential for improve-
ment of efﬁciency of catheter ablation of persistent AF.9. The mechanism of persistent AF from the procedural point
of view
The main explanation for the current disappointing ability to
control AF is an incomplete understanding of the mechanism
underlying its maintenance, despite many years of research and
speculation. Over the past 50 years, the multiple wavelet hypoth-
esis has been the dominant mechanistic model of AF. This
hypothesis, ﬁrst postulated by Moe et al., states that AF is the
result of randomly propagating multiple electrical wavelets that
interact in very complex ways, with local excitation limited by the
heterogeneous distribution of refractory periods throughout the
atria [68]. According to this model, the number of wavelets at any
point in time depends on the atrial conduction velocity, refractory
period, and mass. Perpetuation of AF is favored by slowed
conduction, shortened refractory periods, and increased atrial
mass. The shorter the wavelength is, the higher the number of
wavelets there are. The presence of more wavelets makes perpe-
tuation of AF more stable.
The so-called driver hypothesis has been posited in the recent
years. Optical mapping studies in isolated sheep hearts have
suggested that at least some cases of AF can be maintained by
high-frequency reentrant sources (rotors), usually located in the
posterior LA, which result in spatially distributed frequency
gradients [69,70]. High-frequency rotors maintain AF through
ﬁbrillatory conduction to the remainder of the atria. From the
clinical point of view, in patients with paroxysmal AF, this
hypothesis is supported by the fact that high-frequency activity
within the PV continues even after the restoration of sinus rhythm
in the atria [71]. Presence of a left-to-right atrial frequency gradient
in patients with paroxysmal AF also supports this hypothesis [72]. In
persistent AF, however, electrophysiologists experience some
responses of AF dynamics to ablation that are not consistent with
the ﬁndings estimated from the driver hypothesis. For example,
there is no left-to-right atrial frequency gradient in patients with
persistent AF [72]. It is rare to ﬁnd sites of DFmax in the PV region,
Fig. 2. Spectral analysis of atrial ﬁbrillation. Electrograms recorded from the coronary sinus and lead V1 were processed, and the dominant frequency (DF) was determined
by fast Fourier transformation. Shown are the 12-lead ECG (Panel A) and the periodograms (Panel B) at baseline and after radiofrequency catheter ablation. The DF in the
coronary sinus (CS) decreased from 7.03 Hz to 6.21 Hz after ablation in this patient [58].
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atria has never been observed. A cumulative effect is frequently
observed in ablation of persistent AF. Haı¨ssaguerre et al. reported
that although stepwise ablation was performed in a randomized
order (PVI, atrial ablation, and coronary sinus/superior vena cava
ablation), the number of patients with termination of AF increased
as these procedural steps were completed [47]. It is a common
ﬁnding that sites where radiofrequency application terminated AF
had been previously ablated [73]. Taken together, it is difﬁcult for
the driver hypothesis alone to explain the ﬁndings observed duringthe procedure. One of the possibilities that can account for these
ﬁndings might be the presence of multiple AF drivers, but this has
not been proven in humans.10. Complications
Because the major purpose of catheter ablation of AF is to
improve patients’ quality of life, and its efﬁcacy in improving
survival has not been proven, the probability and severity of
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electrophysiologists, and patients should only undergo AF abla-
tion after carefully weighing the risks and beneﬁts of the
procedure. Because AF ablation is one of the most complex
interventional procedures performed, the risk associated with
this procedure is estimated to be higher than that of the
procedures to treat other arrhythmias. Although prospective
studies surveying the mortality rates associated with AF ablation
procedures are lacking, a worldwide retrospective survey of
prevalence and causes of fatal outcomes in AF ablation reported
that lethal adverse events occurred in 0.1% of patients undergoing
AF ablation [74]. Major causes of fatal outcomes were tamponade,
stroke, and atrioesophageal ﬁstula. More recently, predictors of
complications and 30-day readmissions were identiﬁed from the
data from the California State Inpatient Database [75]. Five
percent of patients experienced periprocedural complications,
and almost 10% were rehospitalized within 30 days. One patient
died during the index admission, and 9 patients died during the
30-day rehospitalization, resulting in a mortality rate of 0.24%.
These rates are quite high when one considers that AF itself is not
a life-threatening arrhythmia.
Because a delay in the diagnosis of tamponade is fatal,
continuous monitoring of systemic arterial pressure during and
following AF ablation is mandatory. Although the majority of
episodes of tamponade can be managed by immediate percuta-
neous drainage, surgical drainage and repair are sometimes
needed. Thus, AF ablation should only be performed in hospitals
equipped to provide emergency surgical support when required.
Oral et al. reported that AF ablation is associated with early
postprocedure thromboembolism, regardless of both the post-
procedure rhythm and whether the patient has risk factors for
stroke. The most likely cause was thought to be char and/or
thrombus formation at sites of LA endocardial ablation, and the
probability was 1.0% [76]. Thus, heparin anticoagulation with
close attention to maintaining a therapeutic dose (activated
clotting time (ACT) of at least 300–350 s) during the procedure
is important. Data regarding the risk of thromboembolism with
and without warfarin after AF ablation is limited. Because
symptomatic or asymptomatic AF may recur during long-term
follow-up after an AF ablation procedure [31], discontinuation of
warfarin therapy post-ablation generally is not recommended in
patients who have a CHADS2 score Z2 [6]. Although the use of
dabigatran has increased in clinical practice, an observational
study with a matched-control design reported that periprocedural
dabigatran use signiﬁcantly increased the risk of bleeding or
thromboembolic complications compared with uninterrupted
warfarin therapy in patients undergoing AF ablation [77]. Large
randomized controlled studies are required to conﬁrm this result.
Development of an atrial–esophageal ﬁstula is one of the most
dreaded complications of AF ablation [78]. A relatively large-scale
nonrandomized study revealed that the anatomical risk factor of a
small LA-to-esophageal distance was the most important factor in
esophageal ulceration when using an irrigation-tip catheter at an
energy setting of 25 W at the posterior left atrium. Most of the
patients who developed an atrial–esophageal ﬁstula in this study
died (7/9 patients, 78%) [74], and it is vital to avoid this
complication. The most common practice is to decrease power
delivery, decrease tissue contact pressure, and move the ablation
catheter every 10–20 s when in close proximity to the esophagus.
A number of other approaches are also used to avoid the
development of an atrial–esophageal ﬁstula [79–84], including
temperature monitoring of the esophagus, use of pain as an assay
for potential esophageal injury, the use of capsule endoscopy after
AF ablation, and mechanical displacement of the esophagus
during the AF procedure. Yamasaki et al. showed that low body
mass index is a predictor for esophageal injury even at low energysettings of radiofrequency delivery [85]. Because Asian people are
generally thinner than people in other regions of the world, the
risk of esophageal injury must always be considered in each
patient undergoing ablation of AF.11. Future direction
The mechanisms of AF are very complex and even somewhat
mysterious. While it may not be easy to attain a greater under-
standing of the mechanism of AF or to discover clearer guidance
on catheter ablation, research on AF nonetheless leads to a better
understanding of other cardiac and non-cardiac diseases because
AF develops multifactorially in association with various under-
lying systemic pathophysiologies. To understand AF is to under-
stand the whole body. It is our goal and hope as a next step to
promote catheter ablation as a ﬁrst-line therapy in more patients
with AF based on deﬁnitive evidence that the procedure reduces
mortality and morbidity.Conﬂict of interest
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